loratadine / Generic mfg. - LARVOL DELTA

Management Considerations for Dermatologic Toxicities Associated With Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (IMW 2023) - P1, P2 | "Management of dermatologic AEs included a heavy moisturizer for general dryness; ammonium lactate 12% lotion twice daily (BID) for hand and foot peeling; loratadine 10 mg oral tablet daily for 3–5 days post dose and triamcinolone 0.1% cream BID for pruritus, injection-site reaction, and rash; and nail hardeners, topical vitamin E oil, and triamcinolone 0.025% ointment for nail thinning and peeling. Talquetamab is an effective therapy for patients with RRMM. Skin and nail AEs are common but are primarily low grade with no discontinuations. Appropriate management, education, and supportive care ensure that patients can stay on treatment to receive optimal benefit from talquetamab."

Clinical • Dermatology • Hematological Malignancies • Multiple Myeloma • Oncology • Pruritus

Effect of Xiaoqinglong decoction on gut-lung axis microbiota in allergic rhinitis mice. (PubMed, Front Microbiol) - "An ovalbumin-induced AR mouse model was established, with mice assigned to control, AR, loratadine, and XQLD groups...Several nasal and gut taxa were significantly associated with nasal symptoms and Th2-related inflammatory indicators. XQLD differentially modulates the gut-lung axis microbiota in AR mice, with the most marked changes observed in the gut, which may correlate with its therapeutic effects and merit further mechanistic exploration."

Journal • Preclinical • Allergic Rhinitis • Immunology • Inflammation • IL4

Second-generation H1 antihistamines for the treatment of chronic urticaria: a network meta-analysis. (PubMed, Front Med (Lausanne)) - "To evaluate the efficacy and safety of 10 commonly used second-generation H1 antihistamines (cetirizine, levocetirizine, loratadine, desloratadine, ebastine, bilastine, olopatadine, rupatadine, fexofenadine, and mizolastine) at licensed doses in treating chronic urticaria using network meta-analysis. In addition, fexofenadine had the lowest incidence of adverse reactions. However, the conclusions of this study still need to be validated by further high-quality randomized controlled trials."

Journal • Retrospective data • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Antineoplastic Activity of the Combination Loratadine-Simvastatin-Gefitinib in HPV-Positive Cervical Cancer Cells: In Vitro and In Vivo Studies. (PubMed, Cancers (Basel)) - "Here, we evaluated the antineoplastic potential of loratadine and simvastatin alone and in combination with cisplatin and gefitinib in HPV-positive CC cells. Drug combinations at relatively low concentrations (IC20) significantly enhanced the anticancer effects on CC cells in in vitro and in vivo settings. These findings support the potential of drug repurposing and combination strategies as promising approaches to decrease adverse side effects while improving therapeutic efficacy for the benefit of CC patients."

Journal • Preclinical • Cervical Cancer • Oncology • Solid Tumor • ANXA5

Serum Peptidomic Analysis in a Comparative Study of the Efficacy of Benjakul Remedy Versus Loratadine in Allergic Rhinitis Patients. (PubMed, Int J Mol Sci) - "By comparison, 3 weeks loratadine treatment significantly downregulated E2F transcription factor 3 (E2F3) and general transcription factor IIIC subunit 6 (GTF3C6) (p = 0.034 and 0.017) and upregulated CTD small phosphatase like 2 (CTDSPL2), suggesting a distinct but complementary anti-inflammatory mechanism. Together, these findings enhance the understanding of AR pathophysiology and may help to elucidate the mechanisms of BJK remedy and loratadine in treatment, supporting the further development of targeted therapies and biomarkers."

Clinical • IO biomarker • Journal • Allergic Rhinitis • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • E2F1 • E2F3 • PDLIM4 • TCF3 • TCF4 • UBQLN1 • ZFHX3

New-Onset Seizure Following Loratadine and Alcohol Ingestion: A Case Report. (PubMed, Cureus) - "Initial vital signs and glucose levels were normal, but on examination, the patient had a Glasgow Coma Scale of 3 with rightward eye deviation and developed tonic-clonic seizures, which were quickly controlled with 4 mg of intravenous (IV) lorazepam. She gradually regained responsiveness and received 3200 mg of levetiracetam IV...The patient recovered fully without further seizures and was not prescribed antiepileptic medication upon discharge. We present the case to document a potential seizure provoked by the combined ingestion of loratadine and alcohol."

Journal • Allergy • CNS Disorders • Epilepsy • Immunology • Strabismus

Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI) (clinicaltrials.gov) - P2 | N=98 | Recruiting | Sponsor: Val Adams | Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Enrollment open • Oncology • Solid Tumor • PD-L1

Catholic Doctrine Supports Religious Exemption to COVID-19 Vaccine Mandates. (PubMed, Linacre Q) - "In this commentary, we demonstrate that the association of COVID-19 vaccines and certain OTC drugs (aspirin, ibuprofen, Benadryl, and Claritin) with past abortions is not equivalent. We outline the Catholic church's position on the use of medicines with an association with elective abortions and demonstrate how Catholic doctrine supports religious-exemptions to COVID-19 vaccine mandates citing a tenet of the faith, respect for all human life."

Journal • Infectious Disease • Novel Coronavirus Disease

Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials. (PubMed, BMJ) - "Among patients with atopic dermatitis, adding H1 antihistamines probably results in a clinically unimportant reduction in atopic dermatitis severity and itch severity, and may not reduce sleep disturbance or atopic dermatitis exacerbations. First generation agents increase cognitive impairment and may increase treatment discontinuation because of adverse events. Cognitive impairment risk differs among second generation agents. These findings provide evidence against routine antihistamine use in atopic dermatitis management and will inform updated clinical guidelines."

Clinical • Journal • Retrospective data • Review • Alzheimer's Disease • Atopic Dermatitis • CNS Disorders • Cognitive Disorders • Dermatitis • Dermatology • Immunology • Sleep Disorder

Investigation of the Anti-Toxoplasma gondii Potential of Loratadine. (PubMed, Pathogens) - "Additional medicinal chemistry, pharmacokinetic, mechanistic, and confirmatory preclinical studies will be required to determine its potential for anti-T. gondii drug development."

Journal • Infectious Disease

COMBINED SECOND HARMONIC AND LINEAR LIGHT SCATTERING AS A TOOL FOR SOLUBILITY AND AGGREGATION SCREENING. (PubMed, Eur J Pharm Sci) - "LLS, which reports on particle size/number, detected precipitation onsets typically close to or below HPLC values and could resolve particle formation down to ∼0.1 µM for pimozide, substantially exceeding the sensitivity of standard nephelometric methods. SHS, which is sensitive to interfacial asymmetry and nonlinear susceptibility, often showed onsets and complex peak-drop-rise patterns that deviated from LLS, particularly for lopinavir, loratadine, and ritonavir, indicating structurally distinct, largely centrosymmetric drug-rich assemblies above the solubility limit. Orthogonal characterization by scanning electron microscopy, Capflex (capillary flow with a hydrophobic fluorescent tracer), and confocal fluorescence microscopy provided independent evidence for droplet-like or amorphous drug-rich domains that preceded bulk precipitation. Together, the results showed that combined SHS-LLS enabled highly sensitive detection of precipitation, while revealing..."

Journal

The impact of antihistamine use on allergic reactions in pregnancy. (PubMed, Drug Metab Pers Ther) - "Physiological changes during pregnancy modify the pharmacokinetic parameters of drugs, reducing plasma protein concentrations by 20-40 %, However, cetirizine and loratadine demonstrate a favourable safety profile based on data from more than 186,000 exposures in Scandinavian registries, and the relative infant dose remains below the 5 % safety threshold. The findings support the use of second-generation antihistamines as first-line therapy for allergic diseases in pregnancy and provide an evidence base for selecting safe pharmacological agents at different gestational stages."

Journal • Allergy

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (clinicaltrials.gov) - P3 | N=284 | Recruiting | Sponsor: Sanofi | N=208 ➔ 284 | Trial completion date: Oct 2025 ➔ Aug 2027 | Trial primary completion date: Mar 2025 ➔ Jun 2027

Enrollment change • Trial completion date • Trial primary completion date • Dermatology • Pruritus

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (clinicaltrials.gov) - P3 | N=208 | Recruiting | Sponsor: Sanofi

New P3 trial • Dermatology • Pruritus

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) (clinicaltrials.gov) - P3 | N=208 | Recruiting | Sponsor: Sanofi | Trial completion date: Jun 2025 ➔ Oct 2025

Trial completion date • Dermatology • Pruritus

Acupoint catgut embedding for allergic rhinitis: a randomized controlled trial (PubMed, Zhongguo Zhen Jiu) - "The control group received oral loratadine tablets...The total effective rate in the observation group was 95.0% (38/40), higher than 82.5% (33/40) in the control group (P<0.05). Acupoint catgut embedding could improve clinical symptoms in patients with AR, and may exert its therapeutic effect by modulating immune balance."

Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • IFNG • IL12A • IL13 • IL4

Comparison of the Efficacy of Different Doses of Glucocorticoid Nasal Spray Combined with Loratadine in the Treatment of Rhinitis in Children: A Randomized Clinical Trial. (PubMed, Iran J Allergy Asthma Immunol) - "The percentages of CD4+ and CD8+ T cells, IL-10 content, and clinical efficacy in groups II and III were significantly higher than those in group I, while the immunoglobulin E (IgE), IL-6 and IL-17 content, the quantitative Lund-Kennedy score of nasal endoscopy, the children's nasal symptom scores, the RQLQ scores, and the incidence rate of adverse events were below in group I. No significant differences were found between groups II and III in all indices, nor in treatment compliance across the three groups. Loratadine combined with a glucocorticoid nasal spray therapy effectively improves clinical outcomes, inflammation, immune function, symptoms, and quality of life in rhinitis in children, with high clinical application value."

Clinical • Journal • Asthma • Immunology • Inflammation • Otorhinolaryngology • Pediatrics • Pulmonary Disease • Respiratory Diseases • Sinusitis • CD4 • CD8 • IL10 • IL17A • IL6

Forecasting seasonal allergic rhinitis through integrated analysis of social media and online drug sales data. (PubMed, World Allergy Organ J) - "We analyzed daily data for urban Beijing from March 1, 2022 to October 15, 2024, including pollen concentration (grains per 1000 mm3), the Baidu search index for "allergic rhinitis," and online purchase rates of 4 oral second-generation H1-antihistamines (loratadine, desloratadine, cetirizine, levocetirizine) from the Meituan platform, standardized per 100,000 population. The ARIMAX (1,1,1) model integrating both pollen and Baidu Index achieved the best forecasting performance (1-day RMSE = 3.80, MAPE = 7.68%, PCC = 0.89) and consistently outperformed single-predictor models and the random-walk benchmark across all horizons. Pollen exposure influences antihistamine demand both directly and indirectly through public information-seeking behavior captured by the Baidu Index, and integrating environmental and digital data enables timely surveillance of seasonal allergic-rhinitis-related medication use."

Journal • Allergic Rhinitis • Immunology • Inflammation

Efficacy and safety of rivaroxaban, colchicine, and famotidine-loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial. (PubMed, Lancet Infect Dis) - "In participants with long COVID, severe fatigue reduced in all study groups-including the no drug group-over 12 weeks, with small additional reductions in the colchicine and famotidine-loratadine groups compared with the no drug group. Modest effects on FAS were not sustained after drug withdrawal. Long-term long COVID symptom benefit is unlikely with these drugs alone. Future trials could investigate the use of these or other repurposed drugs in specific subgroups of patients with long COVID, combination therapies, and how care is delivered."

Journal • Fatigue • Infectious Disease • Novel Coronavirus Disease

Repurposing loratadine to induce ferroptosis and overcome multidrug resistance: preclinical evidence in KB-V-1 cells. (PubMed, Front Oncol) - "Ferroptosis was verified using specific inhibitors, including ferrostatin-1, liproxstatin-1, and deferoxamine, and compared with the pan-caspase inhibitor Z-VAD-FMK to exclude apoptosis...In vivo antitumor efficacy was examined in a KB-V-1 xenograft model following treatment with loratadine (20 mg/kg, intraperitoneal), paclitaxel, or their combination...Loratadine induces ferroptosis in MDR1-overexpressing cells via cystine uptake inhibition, glutathione depletion, and PERK-eIF2α-ATF4 activation, while concurrently downregulating MDR1/P-glycoprotein. These findings support loratadine as a clinically actionable repurposing candidate for ferroptosis-based, resistance-directed cancer therapy."

Journal • Preclinical • Oncology • ABCB1 • ATF4 • CHAC1 • DDIT3 • DDIT4

Not so innocent after all: H1-antihistamine-induced Fixed Drug Eruption confirmed by lesional Patch Testing (BAD 2026) - "H1-antihistamines can be grouped by chemical structure into alkylamines (chlorphenamine), piperazines (hydroxyzine and cetirizine) and piperidines (loratadine and fexofenadine)...Symptoms persisted despite oral prednisolone but improved rapidly after stopping antihistamines...Repeat patch testing with fexofenadine and diphenhydramine is planned to assess cross-sensitivity. This case describes a rare antihistamine-associated fixed drug eruption with postulated class-related crossreactivity in a presumed safe drug class and highlights in situ patch testing as a safe diagnostic tool."

Immunology • Inflammation • Urticaria

Not so innocent after all: H1-antihistamine-induced Fixed Drug Eruption confirmed by lesional Patch Testing (BAD 2026) - "H1-antihistamines can be grouped by chemical structure into alkylamines (chlorphenamine), piperazines (hydroxyzine and cetirizine) and piperidines (loratadine and fexofenadine)...Symptoms persisted despite oral prednisolone but improved rapidly after stopping antihistamines...Repeat patch testing with fexofenadine and diphenhydramine is planned to assess cross-sensitivity. This case describes a rare antihistamine-associated fixed drug eruption with postulated class-related crossreactivity in a presumed safe drug class and highlights in situ patch testing as a safe diagnostic tool."

Immunology • Inflammation • Urticaria

Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers (clinicaltrials.gov) - P=N/A | N=88 | Recruiting | Sponsor: Alexandria University | Trial completion date: Jul 2026 ➔ Jul 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Musculoskeletal Pain • Neutropenia • Oncology • Pain

Pharmaceutical care in self-medication: ABC/VED analysis of over-the-counter antiallergic medicines. (PubMed, Ceska Slov Farm) - "The integrated ABC/VED approach is an effective tool for identifying priority OTC antiallergic medicines, supporting rational pharmacy assortment management, supporting evidence-based practice and pharmaceutical care in self-medication under limited healthcare resources."

Journal • Allergy • Immunology

Optimizing Ancillary Therapies With Immune Checkpoint Inhibitors for Solid Tumors (OAT ICI) (clinicaltrials.gov) - P2 | N=98 | Not yet recruiting | Sponsor: Val Adams

Checkpoint inhibition • New P2 trial • Oncology • Solid Tumor • PD-L1